GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
{{output}}
Pharmacological treatment of type 2 diabetes has been enriched during recent years, with the launch of incretin therapies targeting glucagon-like peptide-1 (GLP-1). Such medications comprise either GLP-1 receptor agonists, with short (one or two daily injectio... ...
